In 2023, Emil D. Kakkis, M.D., Ph.D. earned $2.07M in total compensation at Ultragenyx Pharmaceutical, including $823.69K salary and $622.70K bonus. Most recently sold 20,000 shares in Sep 2024. Currently holds stock worth $103.31M. Has donated $10.05M in stock to charitable causes. Led Ultragenyx Pharmaceutical as CEO for 8 years.
Compensation History
Annual executive compensation data for Emil D. Kakkis, M.D., Ph.D., including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$2.07M
Salary
$823.69K
Bonus
$622.70K
Other
$622.66K
Salary
$823.69KBoard Justification
The compensation philosophy aims to attract and retain a highly-skilled team of executives, aligning their interests with those of stockholders by rewarding performance that increases stockholder value.
Bonus
$622.70KBoard Justification
The bonus for fiscal 2023 was based solely on corporate performance, with a total achievement score of 94% resulting in a bonus of 75% of base salary.
Other Compensation
$622.66KBoard Justification
This includes 401(k) matching contributions and other benefits.
Restricted Stock
Board Justification
No stock grants were vested in 2023; only stock options and RSUs are reported, which are not included in total compensation calculations.
Performance Metrics
The performance metrics for 2023 included corporate goals related to revenue growth, clinical trial enrollment, and operational efficiency, with an overall achievement score of 94%.
Emil D. Kakkis, M.D., Ph.D.
Founder and Ex-CEO of Ultragenyx Pharmaceutical
Education
M.D. and Ph.D. from the University of California, San Francisco
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
Born
July 1, 1968 - 57 years ago
CEO of Ultragenyx Pharmaceutical for
8 years 11 months (Oct 2014 - Sep 2023)
Previous Experience
Founder and CEO of Ultragenyx Pharmaceutical Inc.
Other Ultragenyx Pharmaceutical CEOs
Holdings
Track Emil D. Kakkis, M.D., Ph.D.'s stock holdings and portfolio value over time.
Total Stock Sold
$41.85M
$41.85M
540,325 RARE shares
What if they kept their stock?
If Emil D. Kakkis, M.D., Ph.D. didn't sell their stock, today they would have:
Extra RARE540,325 shares worth $19.58M.
This is -53.23% and $22.28M less than what they got when they sold the stock.
Charitable Transactions
277,291 shares
RARE
Recent Charitable Transactions
50,000 shares
RARE
Dec 31, 2021
Charity
181,670 shares
RARE
Dec 31, 2020
Charity
27,500 shares
RARE
Dec 31, 2016
Charity
18,121 shares
RARE
Dec 31, 2015
Charity
Insider Trading
Emil D. Kakkis, M.D., Ph.D.'s recent stock transactions, purchases, and sales filed with the SEC.
$1.12M
RARE at $55.85/share
Sep 3, 2024
Sale
$1.00M
RARE at $50.17/share
Aug 6, 2024
Sale
41,560 shares
RARE
Mar 1, 2024
Received
$1.35M
RARE at $45.00/share
Feb 7, 2024
Sale
$1.44M
RARE at $47.87/share
Dec 29, 2023
Sale
$1.60M
RARE at $33.52/share
Oct 19, 2023
Sale
54,916 shares
RARE
Mar 1, 2023
Received
$892.35K
RARE at $45.57/share
Dec 30, 2022
Sale
52,041 shares
RARE
Mar 1, 2022
Received
50,000 shares
RARE
Dec 31, 2021
Charity
Rivals
Compare Emil D. Kakkis, M.D., Ph.D. with competitor CEOs and industry peers.